Lonza is set to invest CHF10m to expand its Singapore manufacturing plant which is a part of its custom biomanufacturing business.
Subscribe to our email newsletter
The expansion will add 1858m² of space and associated equipment and support cell line construction, upstream and downstream process development, and a range of analytical services.
The expanded facility expects to offer customers a range of services from development through pre-clinical and small-scale manufacturing, to large-scale commercial supply.
Lonza Development Services head Janet White said they are looking forward to offering the full range of GS Gene Expression System and other technologies in Asia.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.